Cipla Launches Authorized Generic of Aloxi

Cipla USA, Inc. has announced the launch of an authorized generic version of Aloxi in the US under applicable agreements with Helsinn Healthcare SA, in response to the at-risk launch by Teva.

Aloxi – palonosetron hydrochloride injections (0.25 mg base/5 ml) – is indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy and for prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

Helsinn Healthcare SA currently manufactures and markets Aloxi in the US through its licensee Eisai Inc. and its affiliate Helsinn Therapeutics (US) Inc. According to IMS Health, the brand had U.S. sales of approximately $460-mn for the 12-month period ending November 2017.